-+ 0.00%
-+ 0.00%
-+ 0.00%

Eton Pharma buys US commercialization rights to leishmaniasis drug Impavido from Knight affiliate

PUBT·05/19/2026 20:46:20
Listen to the news
Eton Pharma buys US commercialization rights to leishmaniasis drug Impavido from Knight affiliate
  • Eton Pharmaceuticals signed a supply and distribution agreement to acquire exclusive U.S. commercialization rights to IMPAVIDO (miltefosine) from a Knight Therapeutics affiliate.
  • The rights take effect on Sep. 26, 2026, adding another planned 2026 product launch to Eton’s rare-disease portfolio.
  • IMPAVIDO is the only FDA-approved oral therapy for certain forms of leishmaniasis, a rare parasitic disease that can be life-threatening if untreated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-017799), on May 19, 2026, and is solely responsible for the information contained therein.